Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations

This source preferred by Wei-Jun Liang

Authors: Bunten, H., Liang, W.-J., Pounder, D. and Osselton, D.M.

http://eprints.bournemouth.ac.uk/18477/

http://jatox.com/

Journal: Journal of Analytical Toxicology

Volume: 35

Pages: 431-437

This data was imported from PubMed:

Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.

http://eprints.bournemouth.ac.uk/18477/

Journal: J Anal Toxicol

Volume: 35

Issue: 7

Pages: 431-437

eISSN: 1945-2403

Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.

This data was imported from Scopus:

Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.

http://eprints.bournemouth.ac.uk/18477/

Journal: Journal of Analytical Toxicology

Volume: 35

Issue: 7

Pages: 431-437

eISSN: 1945-2403

ISSN: 0146-4760

DOI: 10.1093/anatox/35.7.431

Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.

This data was imported from Web of Science (Lite):

Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.

http://eprints.bournemouth.ac.uk/18477/

Journal: JOURNAL OF ANALYTICAL TOXICOLOGY

Volume: 35

Issue: 7

Pages: 431-437

ISSN: 0146-4760

DOI: 10.1093/anatox/35.7.431

This data was imported from Europe PubMed Central:

Authors: Bunten, H., Liang, W.J., Pounder, D.J., Seneviratne, C. and Osselton, D.

http://eprints.bournemouth.ac.uk/18477/

Journal: Journal of analytical toxicology

Volume: 35

Issue: 7

Pages: 431-437

eISSN: 1945-2403

ISSN: 0146-4760

Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and μ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.

The data on this page was last updated at 04:53 on April 22, 2019.